Encorafenib/Binimetinib Continuation Sub-Study for Participants From the C4221016 (STARBOARD) and C4221023 (PORTSIDE) Studies

An open-label continuation study for participants continuing from encorafenib/binimetinib clinical studiess

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202605826796503

Enrollment

Registered

2026-05-29

Start date

2022-07-05

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Encorafenib

Binimetinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any participant who is receiving study intervention and deriving clinical benefit (as determined by the principal investigator) in an encorafenib/binimetinib Parent Study, with no ongoing NCI CTCAE version 4.03 Grade =3 or intolerable Grade 2 AEs considered to be related to study treatment. Participants must agree to follow the reproductive criteria as outlined in the applicable Encorafenib/Binimetinib Continuation Sub-Study Protocol.

Exclusion criteria

Exclusion criteria: Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study

Design outcomes

Primary

Measure	Time frame
Number of participants with adverse events leading to permanent discontinuation of study intervention;Number serious adverse events reported for all participants	—

Countries

South Africa

Contacts

Public ContactBha Ndugane Tlakula

Medical Director

bha.tlakula@pfizer.com+27113206049

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026